Tim T Y Lau

770 total citations
35 papers, 573 citations indexed

About

Tim T Y Lau is a scholar working on Infectious Diseases, Pharmacology and Epidemiology. According to data from OpenAlex, Tim T Y Lau has authored 35 papers receiving a total of 573 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Infectious Diseases, 9 papers in Pharmacology and 8 papers in Epidemiology. Recurrent topics in Tim T Y Lau's work include Antimicrobial Resistance in Staphylococcus (13 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Antibiotic Use and Resistance (5 papers). Tim T Y Lau is often cited by papers focused on Antimicrobial Resistance in Staphylococcus (13 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and Antibiotic Use and Resistance (5 papers). Tim T Y Lau collaborates with scholars based in Canada, United States and Qatar. Tim T Y Lau's co-authors include Mary H. H. Ensom, Peter J. Zed, Emily Black, Kyle John Wilby, William Bowie, Samuel E. Gilchrist, Yves A. DeClerck, U. Margaretha Wallon, Christopher M. Overall and Stephen Shalansky and has published in prestigious journals such as Journal of Biological Chemistry, Annals of the New York Academy of Sciences and Clinical Microbiology and Infection.

In The Last Decade

Tim T Y Lau

35 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tim T Y Lau Canada 15 187 147 103 96 81 35 573
Francesco Sbrana Italy 16 159 0.9× 119 0.8× 65 0.6× 196 2.0× 266 3.3× 92 823
Markus Mieth Germany 16 120 0.6× 74 0.5× 84 0.8× 259 2.7× 252 3.1× 81 817
Qiquan Wan China 15 85 0.5× 116 0.8× 37 0.4× 272 2.8× 122 1.5× 56 615
Raf Mertens United States 12 167 0.9× 31 0.2× 101 1.0× 108 1.1× 142 1.8× 28 632
Mimi Lou United States 13 146 0.8× 74 0.5× 84 0.8× 88 0.9× 22 0.3× 37 569
Simona Iftimie Spain 13 153 0.8× 45 0.3× 132 1.3× 99 1.0× 83 1.0× 38 435
Hassan Gandjini France 10 164 0.9× 374 2.5× 162 1.6× 356 3.7× 180 2.2× 14 1.1k
Christian Eckmann Germany 11 119 0.6× 273 1.9× 82 0.8× 242 2.5× 190 2.3× 23 925
Susan Raber United States 14 132 0.7× 283 1.9× 51 0.5× 168 1.8× 40 0.5× 33 628
Pilar Luqué Spain 13 113 0.6× 69 0.5× 46 0.4× 236 2.5× 93 1.1× 42 701

Countries citing papers authored by Tim T Y Lau

Since Specialization
Citations

This map shows the geographic impact of Tim T Y Lau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tim T Y Lau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tim T Y Lau more than expected).

Fields of papers citing papers by Tim T Y Lau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tim T Y Lau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tim T Y Lau. The network helps show where Tim T Y Lau may publish in the future.

Co-authorship network of co-authors of Tim T Y Lau

This figure shows the co-authorship network connecting the top 25 collaborators of Tim T Y Lau. A scholar is included among the top collaborators of Tim T Y Lau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tim T Y Lau. Tim T Y Lau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stukas, Sophie, George Goshua, Catherine M. Biggs, et al.. (2022). Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study. The Lancet Regional Health - Americas. 11. 100228–100228. 6 indexed citations
2.
Gorman, Sean K, et al.. (2017). Roles of Infectious Diseases Consultant Pharmacists and Antimicrobial Stewardship Pharmacists: A Survey of Canadian Tertiary Care Academic Hospitals. The Canadian Journal of Hospital Pharmacy. 70(6). 415–422. 5 indexed citations
3.
Wilby, Kyle John, et al.. (2017). A Review of Clinical Outcomes Associated with Two Meropenem Dosing Strategies. Drugs in R&D. 17(1). 73–78. 1 indexed citations
4.
So, Miranda, Muhammad Mamdani, Andrew M. Morris, et al.. (2017). Effect of an antimicrobial stewardship programme on antimicrobial utilisation and costs in patients with leukaemia: a retrospective controlled study. Clinical Microbiology and Infection. 24(8). 882–888. 25 indexed citations
5.
Wilby, Kyle John, et al.. (2015). Critical appraisal of clinical practice guidelines in pediatric infectious diseases. International Journal of Clinical Pharmacy. 37(5). 799–807. 12 indexed citations
6.
Bryce, Elizabeth, et al.. (2015). Horizontal infection prevention measures and a risk-managed approach to vancomycin-resistant enterococci: An evaluation. American Journal of Infection Control. 43(11). 1238–1243. 16 indexed citations
7.
Zuberi, Daniyal, et al.. (2015). Mobilising for safer care: addressing structural barriers to reducing healthcare-associated infections in Vancouver, Canada. Health Sociology Review. 24(2). 137–151. 2 indexed citations
8.
Legal, Michael, et al.. (2014). Identification of Risk Factors for Nephrotoxicity in Patients Receiving Extended-Duration, High-Trough Vancomycin Therapy. The Canadian Journal of Hospital Pharmacy. 67(2). 126–32. 27 indexed citations
9.
Hussaini, Trana, et al.. (2014). Evaluation of a Once-Daily Vancomycin Regimen in an Outpatient Leukemia/Bone Marrow Transplant Clinic (OD-VANCO Study). The Canadian Journal of Hospital Pharmacy. 67(4). 280–5. 2 indexed citations
10.
11.
Lau, Tim T Y, et al.. (2013). Serotonergic and Adrenergic Drug Interactions Associated with Linezolid: A Critical Review and Practical Management Approach. Annals of Pharmacotherapy. 47(4). 543–560. 34 indexed citations
12.
Wilby, Kyle John, Tim T Y Lau, Samuel E. Gilchrist, & Mary H. H. Ensom. (2012). Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria. Annals of Pharmacotherapy. 46(3). 384–393. 13 indexed citations
13.
Legal, Michael, et al.. (2012). Development and Validation of a Novel Vancomycin Dosing Nomogram for Achieving High-Target Trough Levels at 2 Canadian Teaching Hospitals. The Canadian Journal of Hospital Pharmacy. 65(3). 180–7. 16 indexed citations
14.
Wilby, Kyle John, Tim T Y Lau, Samuel E. Gilchrist, & Mary H. H. Ensom. (2012). Mosquirix (RTS,S): A Novel Vaccine for the Prevention of Plasmodium falciparum Malaria. Annals of Pharmacotherapy. 46(3). 384–393. 25 indexed citations
15.
Simpson, Scot H., Jeffrey Johnson, Karen B. Farris, et al.. (2005). Physician Perceptions of Enhanced Community Pharmacist Care in Cholesterol Management. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada. 138(4). 33–39. 3 indexed citations
16.
17.
Balen, Robert M., et al.. (2004). Perceptions of the Professional Pharmacy Services in a Major Canadian Hospital: A Comparison of Stakeholder Groups. 7(2). 7 indexed citations
18.
Lau, Tim T Y & Peter J. Zed. (2001). Does Ketamine Have a Role in Managing Severe Exacerbation of Asthma in Adults?. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 21(9). 1100–1106. 31 indexed citations
19.
Overall, Christopher M., et al.. (1999). Identification of the Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Binding Site on the Hemopexin Carboxyl Domain of Human Gelatinase A by Site-directed Mutagenesis. Journal of Biological Chemistry. 274(7). 4421–4429. 68 indexed citations
20.
Overall, Christopher M., Heather F. Bigg, Tim T Y Lau, et al.. (1999). Identification of the TIMP‐2 Binding Site on the Gelatinase A Hemopexin C‐Domain by Site‐Directed Mutagenesis and the Yeast Two‐Hybrid System. Annals of the New York Academy of Sciences. 878(1). 747–753. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Sbrana Breakdown of academic impact, for papers by Markus Mieth Breakdown of academic impact, for papers by Qiquan Wan Breakdown of academic impact, for papers by Raf Mertens Breakdown of academic impact, for papers by Mimi Lou Breakdown of academic impact, for papers by Simona Iftimie Breakdown of academic impact, for papers by Hassan Gandjini Breakdown of academic impact, for papers by Christian Eckmann Breakdown of academic impact, for papers by Susan Raber Breakdown of academic impact, for papers by Pilar Luqué
Rankless by CCL
2026